Trial · NCT02795819
Results by group35
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 35
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Recommended Phase 2 Doses (RP2Ds) of AR-42 and Pazopanib When Given in Combination. | Cohort Minus 1 (-1) | 0 | Dose Limiting Toxicities | ||
| The Recommended Phase 2 Doses (RP2Ds) of AR-42 and Pazopanib When Given in Combination. | Cohort 1 | 2 | Dose Limiting Toxicities | ||
| The Recommended Phase 2 Doses (RP2Ds) of AR-42 and Pazopanib When Given in Combination. | Cohort 2 | 0 | Dose Limiting Toxicities | ||
| The Recommended Phase 2 Doses (RP2Ds) of AR-42 and Pazopanib When Given in Combination. | Cohort 3A | 0 | Dose Limiting Toxicities | ||
| The Recommended Phase 2 Doses (RP2Ds) of AR-42 and Pazopanib When Given in Combination. | Cohort 3B | 0 | Dose Limiting Toxicities | ||
| The Recommended Phase 2 Doses (RP2Ds) of AR-42 and Pazopanib When Given in Combination. | Cohort 4A | 0 | Dose Limiting Toxicities | ||
| The Recommended Phase 2 Doses (RP2Ds) of AR-42 and Pazopanib When Given in Combination. | Cohort 4B | 0 | Dose Limiting Toxicities | ||
| Number of Participants With Adverse Events That Were Related to Treatment, AR-42 and Pazopanib Combination. | Cohort Minus 1 (-1) | 0 | Participants | ||
| Number of Participants With Adverse Events That Were Related to Treatment, AR-42 and Pazopanib Combination. | Cohort 1 | 6 | Participants | ||
| Number of Participants With Adverse Events That Were Related to Treatment, AR-42 and Pazopanib Combination. | Cohort 2 | 0 | Participants | ||
| Number of Participants With Adverse Events That Were Related to Treatment, AR-42 and Pazopanib Combination. | Cohort 3A | 0 | Participants | ||
| Number of Participants With Adverse Events That Were Related to Treatment, AR-42 and Pazopanib Combination. | Cohort 3B | 0 | Participants | ||
| Number of Participants With Adverse Events That Were Related to Treatment, AR-42 and Pazopanib Combination. | Cohort 4A | 0 | Participants | ||
| Number of Participants With Adverse Events That Were Related to Treatment, AR-42 and Pazopanib Combination. | Cohort 4B | 0 | Participants | ||
| The Antitumor Effects of the AR-42 and Pazopanib Treatment Regimen in Patients With Advanced Renal Cell Carcinoma (RCC) or Soft Tissue Sarcoma (STS). | Cohort Minus 1 (-1) | Partial Response | 0 | Participants | |
| The Antitumor Effects of the AR-42 and Pazopanib Treatment Regimen in Patients With Advanced Renal Cell Carcinoma (RCC) or Soft Tissue Sarcoma (STS). | Cohort 1 | Partial Response | 1 | Participants | |
| The Antitumor Effects of the AR-42 and Pazopanib Treatment Regimen in Patients With Advanced Renal Cell Carcinoma (RCC) or Soft Tissue Sarcoma (STS). | Cohort 2 | Partial Response | 0 | Participants | |
| The Antitumor Effects of the AR-42 and Pazopanib Treatment Regimen in Patients With Advanced Renal Cell Carcinoma (RCC) or Soft Tissue Sarcoma (STS). | Cohort 3A | Partial Response | 0 | Participants | |
| The Antitumor Effects of the AR-42 and Pazopanib Treatment Regimen in Patients With Advanced Renal Cell Carcinoma (RCC) or Soft Tissue Sarcoma (STS). | Cohort 3B | Partial Response | 0 | Participants | |
| The Antitumor Effects of the AR-42 and Pazopanib Treatment Regimen in Patients With Advanced Renal Cell Carcinoma (RCC) or Soft Tissue Sarcoma (STS). | Cohort 4A | Partial Response | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02795819/results